Tectonic therapeutic announces favorable phase 1a safety, tolerability and pk/pd results for lead program tx45

Tx45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable pk/pd relationship which was used to identify doses for the phase 2 clinical trial
TECX Ratings Summary
TECX Quant Ranking